PriceTargets.com logo

Acumen Pharmaceuticals - ABOS Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $9.00
  • Forecasted Upside: 279.75%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 1 Strong Buy Ratings
$2.37 As of 11/20/2024 01:00 AM ET
▼ -0.02 (-0.84%)

This chart shows the closing price for ABOS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Acumen Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ABOS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ABOS

Analyst Price Target is $9.00
▲ +279.75% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Acumen Pharmaceuticals in the last 3 months. The average price target is $9.00, with a high forecast of $15.00 and a low forecast of $6.00. The average price target represents a 279.75% upside from the last price of $2.37.

This chart shows the closing price for ABOS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 4 contributing investment analysts is to buy stock in Acumen Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2024
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2024
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2024
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/13/2024HC WainwrightReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
10/3/2024HC WainwrightReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
8/15/2024UBS GroupLower TargetBuy ➝ Buy$14.00 ➝ $6.00
8/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
7/26/2024CitigroupUpgradeStrong-Buy
7/25/2024CitigroupInitiated CoverageBuy$7.00
5/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$15.00
3/27/2024HC WainwrightReiterated RatingBuy ➝ Buy$15.00
12/12/2023Deutsche Bank AktiengesellschaftInitiated CoverageBuy$8.00
8/9/2023HC WainwrightReiterated RatingBuy ➝ Buy$15.00
8/9/2023Credit Suisse GroupReiterated RatingOutperform ➝ Outperform$13.00
7/20/2023Bank of AmericaInitiated CoverageBuy
5/18/2023Cantor FitzgeraldInitiated CoverageOverweight$13.00
3/28/2023HC WainwrightReiterated RatingBuy$15.00
3/28/2023Credit Suisse GroupLower TargetOutperform$16.00 ➝ $13.00
2/2/2023HC WainwrightReiterated RatingBuy$15.00
11/15/2022Credit Suisse GroupLower TargetOutperform$17.00 ➝ $16.00
10/5/2022BTIG ResearchBoost TargetBuy$15.00 ➝ $22.00
8/16/2022HC WainwrightReiterated RatingBuy$15.00
7/15/2022BTIG ResearchInitiated CoverageBuy$15.00
6/30/2022HC WainwrightInitiated CoverageBuy$15.00
3/29/2022Credit Suisse GroupLower TargetOutperform$26.00 ➝ $17.00
1/21/2022Bank of AmericaUpgradeNeutral ➝ Buy$16.00 ➝ $14.00
7/26/2021UBS GroupInitiated CoverageBuy$27.00
7/26/2021Stifel NicolausInitiated CoverageBuy$27.00
7/26/2021Credit Suisse GroupInitiated CoverageOutperform$26.00
7/26/2021Bank of AmericaInitiated CoverageNeutral$20.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.39 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 6 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2024
  • 5 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/24/2024
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2024
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2024
  • 3 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/22/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2024
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2024
  • 5 very positive mentions
  • 20 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2024

Current Sentiment

  • 5 very positive mentions
  • 20 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Acumen Pharmaceuticals logo
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Read More

Today's Range

Now: $2.37
Low: $2.32
High: $2.43

50 Day Range

MA: $2.61
Low: $2.24
High: $3.27

52 Week Range

Now: $2.37
Low: $2.08
High: $5.09

Volume

180,498 shs

Average Volume

209,143 shs

Market Capitalization

$142.39 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.04

Frequently Asked Questions

What sell-side analysts currently cover shares of Acumen Pharmaceuticals?

The following Wall Street research analysts have issued reports on Acumen Pharmaceuticals in the last twelve months: Citigroup Inc., Deutsche Bank Aktiengesellschaft, HC Wainwright, and UBS Group AG.
View the latest analyst ratings for ABOS.

What is the current price target for Acumen Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Acumen Pharmaceuticals in the last year. Their average twelve-month price target is $9.00, suggesting a possible upside of 279.7%. HC Wainwright has the highest price target set, predicting ABOS will reach $15.00 in the next twelve months. UBS Group AG has the lowest price target set, forecasting a price of $6.00 for Acumen Pharmaceuticals in the next year.
View the latest price targets for ABOS.

What is the current consensus analyst rating for Acumen Pharmaceuticals?

Acumen Pharmaceuticals currently has 3 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ABOS will outperform the market and that investors should add to their positions of Acumen Pharmaceuticals.
View the latest ratings for ABOS.

What other companies compete with Acumen Pharmaceuticals?

Other companies that are similar to Acumen Pharmaceuticals include Paratek Pharmaceuticals, Quince Therapeutics, Ovid Therapeutics, Chiasma and Epizyme. Learn More about companies similar to Acumen Pharmaceuticals.

How do I contact Acumen Pharmaceuticals' investor relations team?

The company's listed phone number is 434-297-1000 and its investor relations email address is [email protected]. The official website for Acumen Pharmaceuticals is www.acumenpharm.com. Learn More about contacing Acumen Pharmaceuticals investor relations.